search
Back to results

Effects of Curcumin in Patients in Chronic Kidney Disease

Primary Purpose

Chronic Kidney Diseases

Status
Unknown status
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Active Comparator: Supplement A
Placebo Comparator: Supplement B
Sponsored by
Denise Mafra
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Chronic Kidney Diseases

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical diagnosis of Chronic Kidney Disease
  • Hemodialysis patients for more than 6 months
  • Aged 18 years or older
  • Must be able to swallow tablets

Exclusion Criteria:

  • Patients pregnant
  • Smokers
  • Using antibiotics in the last 3 months
  • Using antioxidant supplements in the last 3 months
  • Usual intake of turmeric
  • Usual intake Autoimmune
  • Clinical diagnosis of infectious diseases
  • Clinical diagnosis of Cancer
  • Clinical diagnosis of AIDS

Sites / Locations

  • Denise Mafra

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Supplement A

Supplement B

Arm Description

Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks

Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks

Outcomes

Primary Outcome Measures

Antioxidants and anti-inflammatory biomarkers
Get blood samples to evaluate the supplementation effects in antioxidants biomarkers- nuclear receptor factor 2 (Nrf2), glutathioneperoxidase (GPx), heme oxygenase-1 (HO-1)
Inflammatory biomarkers
Get blood samples to evaluate the supplementation effects in inflammatory biomarkers- factor nuclear kappa B (NFkB), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha)

Secondary Outcome Measures

Full Information

First Posted
February 21, 2018
Last Updated
April 29, 2021
Sponsor
Denise Mafra
search

1. Study Identification

Unique Protocol Identification Number
NCT03475017
Brief Title
Effects of Curcumin in Patients in Chronic Kidney Disease
Official Title
Effects of Curcumin Supplementation in Inflammation, Oxidative Stress and Intestinal Microbiota in Patients With Chronic Kidney Disease
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
February 22, 2018 (Actual)
Primary Completion Date
April 29, 2021 (Actual)
Study Completion Date
December 30, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Denise Mafra

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Many studies have been conducted to identify therapeutic strategies to modulate inflammation and oxidative stress, complications that contribute to the increased morbidity and cardiovascular mortality in patients with chronic kidney disease (CKD). Among several non-pharmacological strategies, the use of bioactive compounds has emerged as a potential approach to reduce these complications in CKD patients. In this context, turmeric/curcumin may have positive consequences in terms of cardiovascular and nephroprotection because of its antibacterial, antiviral, anti-inflammatory and anti-oxidative effects. The aim of this study is the role of curcumin as a nutritional strategy to reduce cardiovascular risk factors as inflammation and oxidative stress in CKD patients.
Detailed Description
This is a longitudinal study of the type randomized crossover, double-blind, placebo-controlled, washout period. We selected 30 patients with CKD in hemodialysis at Clínica Renalcor / RJ (second sample calculation, considering p = 0.05 and test power of 80%). Eligible patients of both genders, previously evaluated and authorized by the medical staff of the clinic, were invited to participate in the research. The research was carried out after signing the free and informed consent form, according to the standards of the local Research Ethics Committees and required by Resolution 466 of December 12, 2012 (Conselho Nacional de Saúde), based on the guidelines of the Declaration of Helsinki and of the World Medical Association on human research. This project was approved by the Ethics Committee of the Faculty of Medicine / UFF, number: 2.346.933. It is registered with ClinicalTrials.gov under the number NCT 03475017. Inclusion and exclusion criteria: Patients with stage 5 CKD (GFR <15 mL / min) on hemodialysis for more than 6 months, aged at least 18 years, and who had arteriovenous fistula (AVF) as vascular access were included in the study. Patients who were pregnant, smokers, antibiotics in the last 3 months, antioxidant supplements and habitual turmeric and / or turmeric intake, besides those with autoimmune and infectious diseases, cancer, hepatic diseases and AIDS were not included in the study. The food intake was evaluated at the beginning and at the end of the intervention through the 24-h food recall technique. The analysis of total energy intake (kcal/kg), carbohydrates (%), lipids (%), protein (g/kg), phosphorus (mg) and potassium (mg) were estimated using NutWin® software. Assessment of nutritional status Patients had their body weight (kg), height (m), arm circumference (cm), waist circumference (WC) (cm) and skinfold measurements (mm) (biceps, triceps, subscapular, and suprailiac) measured with the aid of calibrated balance, stadiometer, tape measure and Lange Skinfold Caliper type adipometer (Cambridge Scientific Industries Inc.) before and after intervention. Body mass index (BMI) was calculated from dry body weight (kg) divided by squared height (m). Arm muscle area and body fat percentage were calculated. All measurements were performed after the dialysis session by a trained staff member. Blood collection and biochemical analyzes Samples were collected in the morning after a 12-h fasting before dialysis and immediately after arteriovenous fistula puncture in Vacutainer® tubes containing ethylenediamine tetraacetic acid (EDTA) with anticoagulant (1.0 mg/mL). After collection, an aliquot was used for the analysis with whole blood and another one was centrifuged at 2500 rpm for 10 min at 4 C to obtain the plasma, which was distributed in 1.5 mL polypropylene eppendorfs tubes, identified and aliquoted for each analysis and stored at 80 C for further analysis. The whole blood was used to obtain the peripheral blood mononuclear cells (PBMC). Real time PCR analysis Nrf2, NF-kB mRNA expression were evaluated from PBMC using quantitative real-time polymerase chain reaction (qPCR). TaqMan Gene Expression (Thermo Fisher®) assays for the detection of Nrf2 (Hs00975961_g1), NF-kB (Hs00765730_m1), and GAPDH (Hs02758991_g1) control mRNA expression were used. The Prism 7500 Sequence Detection System ABI (Applied Biosystems®) and the standard cyclic conditions were used for PCR amplification. NRf2, NF-kB mRNA expression were normalized against GAPDH, and the level of expressionwas calculated using the DDCT (delta delta threshold cycle) method. Biochemical parameters Relevant information such as the etiology of CKD and age were collected from patients' records. Routine biochemical exams corresponding to collection dates, such as urea, Kt/v, hemoglobin and albumin, serum phosphorus, potassium, parathyroid hormone, glucose, and glycated hemoglobin were also obtained from routine medical records. Serum levels of high sensitivity C-reactive protein (hsCRP), total cholesterol, triglycerides, c-HDL were determined using BioClin® kits using the biochemical analyzer Bioclin BS-120 Chemistry Analyze. LDL was calculated using the Friedewald equation, considering triglyceride values below 400 mg/dL: LDL Cholesterol ¼ (Total Cholesterol) - (HDL Cholesterol) - (Triglycerides)/5.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Kidney Diseases

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Supplement A
Arm Type
Active Comparator
Arm Description
Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
Arm Title
Supplement B
Arm Type
Placebo Comparator
Arm Description
Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Active Comparator: Supplement A
Other Intervention Name(s)
Curcumin and piperine
Intervention Description
The patients will receive 3 capsules per day containing 500mg of curcumin and 5mg of piperine for 4 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo Comparator: Supplement B
Other Intervention Name(s)
Placebo
Intervention Description
The patients will receive 3 capsules of placebo per day containing 500mg of maize starch for 4 weeks
Primary Outcome Measure Information:
Title
Antioxidants and anti-inflammatory biomarkers
Description
Get blood samples to evaluate the supplementation effects in antioxidants biomarkers- nuclear receptor factor 2 (Nrf2), glutathioneperoxidase (GPx), heme oxygenase-1 (HO-1)
Time Frame
4 weeks
Title
Inflammatory biomarkers
Description
Get blood samples to evaluate the supplementation effects in inflammatory biomarkers- factor nuclear kappa B (NFkB), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha)
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of Chronic Kidney Disease Hemodialysis patients for more than 6 months Aged 18 years or older Must be able to swallow tablets Exclusion Criteria: Patients pregnant Smokers Using antibiotics in the last 3 months Using antioxidant supplements in the last 3 months Usual intake of turmeric Usual intake Autoimmune Clinical diagnosis of infectious diseases Clinical diagnosis of Cancer Clinical diagnosis of AIDS
Facility Information:
Facility Name
Denise Mafra
City
Rio de Janeiro
State/Province
RJ
ZIP/Postal Code
22260050
Country
Brazil

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32204978
Citation
Alvarenga L, Salarolli R, Cardozo LFMF, Santos RS, de Brito JS, Kemp JA, Reis D, de Paiva BR, Stenvinkel P, Lindholm B, Fouque D, Mafra D. Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A pilot randomized, double-blind, controlled study. Clin Nutr. 2020 Dec;39(12):3594-3600. doi: 10.1016/j.clnu.2020.03.007. Epub 2020 Mar 13.
Results Reference
derived

Learn more about this trial

Effects of Curcumin in Patients in Chronic Kidney Disease

We'll reach out to this number within 24 hrs